Apellis Pharmaceuticals, Inc.
APLSNASDAQHealthcare
$41.03
+$0.00(+0.00%)
Market Cap$5.3B
P/E Ratio—
52W High$41.14
52W Low$16.61
Apellis Pharmaceuticals, Inc. (APLS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
APLS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.15
Est. -$0.38 · +139.5%
Revenue
$0.27B
Est. $0.21B · +27.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
APLS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | -$0.33 | — | — | — | $0.21B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.38 | $0.15 | +139.5% | $0.27B | $0.21B | +27.5% |
| ▼ Q1 FY2026 | Feb 24, 2026 | -$0.39 | -$0.47 | -20.5% | $0.20B | $0.20B | +0.3% |
| ▲ Q4 FY2025 | Oct 30, 2025 | $1.03 | $1.67 | +62.1% | $0.46B | $0.20B | +130.1% |
| ▲ Q3 FY2025 | Jul 31, 2025 | -$0.44 | -$0.33 | +25.0% | $0.18B | $0.37B | -52.0% |
| ▼ Q2 FY2025 | May 7, 2025 | -$0.36 | -$0.74 | -105.6% | $0.17B | $0.21B | -20.3% |
| ▲ Q1 FY2025 | Feb 28, 2025 | -$0.37 | -$0.29 | +21.6% | $0.21B | $0.20B | +6.7% |
| ▼ Q4 FY2024 | Nov 5, 2024 | -$0.32 | -$0.46 | -43.8% | $0.20B | $0.19B | +2.6% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
-$0.33
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$0.15
EPS Est.
-$0.38
EPS Surpr.
+139.5%
Revenue
$0.27B
Q1 FY2026
Feb 24, 2026Miss
EPS Actual
-$0.47
EPS Est.
-$0.39
EPS Surpr.
-20.5%
Revenue
$0.20B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
$1.67
EPS Est.
$1.03
EPS Surpr.
+62.1%
Revenue
$0.46B
Q3 FY2025
Jul 31, 2025Beat
EPS Actual
-$0.33
EPS Est.
-$0.44
EPS Surpr.
+25.0%
Revenue
$0.18B
Q2 FY2025
May 7, 2025Miss
EPS Actual
-$0.74
EPS Est.
-$0.36
EPS Surpr.
-105.6%
Revenue
$0.17B
Q1 FY2025
Feb 28, 2025Beat
EPS Actual
-$0.29
EPS Est.
-$0.37
EPS Surpr.
+21.6%
Revenue
$0.21B
Q4 FY2024
Nov 5, 2024Miss
EPS Actual
-$0.46
EPS Est.
-$0.32
EPS Surpr.
-43.8%
Revenue
$0.20B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $1.43 | $1.53 | $1.65 | 6 |
| Q2 FY2028 | $1.31 | $1.41 | $1.52 | 4 |
| Q1 FY2028 | $1.15 | $1.23 | $1.33 | 4 |
| Q4 FY2027 | $-0.24 | $-0.22 | $-0.21 | 3 |
| Q3 FY2027 | $-0.26 | $-0.24 | $-0.22 | 4 |
| Q2 FY2027 | $-0.25 | $-0.23 | $-0.22 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $0.5B | $0.5B | $0.6B | 5 |
| Q2 FY2028 | $0.5B | $0.5B | $0.5B | 3 |
| Q1 FY2028 | $0.4B | $0.4B | $0.5B | 3 |
| Q4 FY2027 | $0.2B | $0.2B | $0.3B | 4 |
| Q3 FY2027 | $0.2B | $0.2B | $0.3B | 5 |
| Q2 FY2027 | $0.2B | $0.2B | $0.2B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +139.5% | $41.12 | $41.01 | -0.27% |
| ▼ Q1 FY2026 | Feb 24, 2026 | -20.5% | $22.47 | $22.13 | -1.51% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +62.1% | $30.05 | $20.73 | -31.01% |
| ▲ Q3 FY2025 | Jul 31, 2025 | +25.0% | $19.00 | $22.34 | +17.58% |
| ▼ Q2 FY2025 | May 7, 2025 | -105.6% | $19.12 | $17.99 | -5.91% |
| ▲ Q1 FY2025 | Feb 28, 2025 | +21.6% | $26.00 | $25.15 | -3.27% |
| ▼ Q4 FY2024 | Nov 5, 2024 | -43.8% | $28.56 | $28.08 | -1.68% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +15.2% | $39.60 | $36.00 | -9.09% |
Q2 FY2026-0.27%
Report Date
May 7, 2026
EPS Beat/Miss
+139.5%
Price Before
$41.12
Price After
$41.01
Q1 FY2026-1.51%
Report Date
Feb 24, 2026
EPS Beat/Miss
-20.5%
Price Before
$22.47
Price After
$22.13
Q4 FY2025-31.01%
Report Date
Oct 30, 2025
EPS Beat/Miss
+62.1%
Price Before
$30.05
Price After
$20.73
Q3 FY2025+17.58%
Report Date
Jul 31, 2025
EPS Beat/Miss
+25.0%
Price Before
$19.00
Price After
$22.34
Q2 FY2025-5.91%
Report Date
May 7, 2025
EPS Beat/Miss
-105.6%
Price Before
$19.12
Price After
$17.99
Q1 FY2025-3.27%
Report Date
Feb 28, 2025
EPS Beat/Miss
+21.6%
Price Before
$26.00
Price After
$25.15
Q4 FY2024-1.68%
Report Date
Nov 5, 2024
EPS Beat/Miss
-43.8%
Price Before
$28.56
Price After
$28.08
Q3 FY2024-9.09%
Report Date
Aug 1, 2024
EPS Beat/Miss
+15.2%
Price Before
$39.60
Price After
$36.00
Avg Beat Reaction-5.21%
Avg Miss Reaction-3.03%
Beat Rate5 / 8 quarters
Largest Move-31.01% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: APLS ends December
Apellis Pharmaceuticals, Inc. (APLS) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.15 — beating the analyst consensus of $-0.38 by +139.5%. The next APLS earnings date is expected around September 1, 2026.
Each quarter, investors track APLS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. APLS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
APLS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
APLS earnings · 5 questionsApellis Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. APLS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; APLS historically reports after market close (AMC).
APLS earnings datewhen is APLS earningsAPLS next earnings datewhen does APLS report earningsAPLS earnings calendar
▸ Source: FMP · Apellis Pharmaceuticals, Inc. SEC filings · US GAAP · Apellis Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026